Literature DB >> 9398859

EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.

W A May1, A Arvand, A D Thompson, B S Braun, M Wright, C T Denny.   

Abstract

EWS/FLI1, a fusion gene found in Ewing's sarcoma, encodes a transcriptional regulator and promotes cellular transformation by modulating the transcription of specific target genes. We have found that EWS/FLI1 and structurally related fusion proteins upregulate manic fringe (MFNG), a recently described member of the Fringe gene family instrumental in somatic development. MFNG is also expressed in human tumour-derived cell lines expressing EWS/FLI1. Overexpression of MFNG in NIH 3T3 cells renders them tumorigenic in mice with severe combined immunodeficiency disease (SCID). These data demonstrate that part of the oncogenic effect of EWS/FLI1 is to transcriptionally deregulate a member of a family of morphogenic genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398859     DOI: 10.1038/ng1297-495

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  34 in total

1.  PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.

Authors:  Benjamin Deneen; Scott M Welford; Thu Ho; Felicia Hernandez; Irwin Kurland; Christopher T Denny
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 2.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

3.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

4.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Authors:  Yoshitaka Miyagawa; Hajime Okita; Hideki Nakaijima; Yasuomi Horiuchi; Ban Sato; Tomoko Taguchi; Masashi Toyoda; Yohko U Katagiri; Junichiro Fujimoto; Jun-Ichi Hata; Akihiro Umezawa; Nobutaka Kiyokawa
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

Review 6.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

7.  Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Authors:  D Herrero-Martín; D Osuna; J L Ordóñez; V Sevillano; A S Martins; C Mackintosh; M Campos; J Madoz-Gúrpide; A P Otero-Motta; G Caballero; A T Amaral; D H Wai; Y Braun; M Eisenacher; K-L Schaefer; C Poremba; E de Alava
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  Protein disorder in the human diseasome: unfoldomics of human genetic diseases.

Authors:  Uros Midic; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

9.  Transdifferentiation-inducing HCCR-1 oncogene.

Authors:  Seon-Ah Ha; Hyun K Kim; JinAh Yoo; SangHee Kim; Seung M Shin; Youn S Lee; Soo Y Hur; Yong W Kim; Tae E Kim; Yeun J Chung; Shin S Jeun; Dong W Kim; Yong G Park; Jin Kim; Soon Y Shin; Young H Lee; Jin W Kim
Journal:  BMC Cell Biol       Date:  2010-06-30       Impact factor: 4.241

Review 10.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.